What is the recommended beta‑blocker regimen for treating symptomatic myocardial bridge?

Beta-Blocker Therapy for Symptomatic Myocardial Bridge

Beta-blockers are the first-line medical therapy for symptomatic myocardial bridge and should be titrated to maximum tolerated doses before considering any additional agents or invasive interventions. 1, 2

Mechanism of Benefit in Myocardial Bridge

• Beta-blockers reduce systolic compression of the tunneled coronary segment through their negative inotropic effect, decreasing the mechanical force exerted by the overlying myocardial bridge during ventricular contraction. 3, 4

• Angiographic studies demonstrate that beta-blockers reduce systolic diameter compression from 83% to 62% and diastolic compression from 41% to 30% within the bridged segment. 3

• Intracoronary Doppler measurements show that beta-blockers normalize the elevated diastolic peak flow velocities that occur within myocardial bridges (reducing from 63 cm/s during tachycardia back to baseline 35 cm/s), eliminating the hemodynamic stress that causes ischemic symptoms. 3

• The negative chronotropic effect prolongs diastolic filling time, which is particularly beneficial since coronary perfusion occurs predominantly in diastole and myocardial bridges cause persistent diastolic compression. 5, 3

Evidence for Clinical Efficacy

• Meta-regression analysis of 899 patients demonstrates that beta-blocker therapy is the strongest predictor of remaining angina-free (B -0.6, P = 0.013), with 78.7% of conservatively managed patients achieving complete symptom resolution. 1

• Echocardiographic strain imaging confirms that beta-blockers improve left ventricular global longitudinal strain in myocardial bridge patients (from -12.57 to -15.92, P < 0.001), providing objective evidence of reduced myocardial stress. 5

• Short-term intravenous beta-blocker administration abolishes ST-segment changes and anginal symptoms during atrial pacing in all studied patients with myocardial bridges. 3

Specific Beta-Blocker Selection and Dosing

• Non-dihydropyridine calcium-channel blockers (verapamil, diltiazem) are acceptable alternatives or additions to beta-blockers for patients who cannot tolerate beta-blockade, as they provide similar negative chronotropic and inotropic effects. 2

• Propranolol has been specifically studied in myocardial bridge and demonstrates angiographic reduction in systolic compression severity, likely through both negative inotropy and increased coronary vascular tone from unopposed alpha-adrenergic effects. 4

• Titrate beta-blockers to achieve resting heart rate of 55–60 beats per minute to maximize diastolic time and minimize systolic compression forces. 3

Critical Contraindications

• Nitrates are absolutely contraindicated in myocardial bridge because they reduce diastolic coronary perfusion pressure and may paradoxically worsen ischemia by increasing the pressure gradient across the compressed segment. 2

• Dihydropyridine calcium-channel blockers should be avoided as monotherapy because their reflex tachycardia and positive inotropic effects can worsen systolic compression. 2

Treatment Algorithm

1. Initiate beta-blocker monotherapy and titrate to maximum tolerated dose (target heart rate 55–60 bpm). 1, 2

2. If symptoms persist despite optimal beta-blockade, add non-dihydropyridine calcium-channel blocker (verapamil or diltiazem) for additional negative chronotropic and inotropic effects. 2

3. Reserve surgical myotomy or coronary artery bypass grafting for patients who remain severely symptomatic despite maximal medical therapy, as surgery achieves 84.5% freedom from angina versus 54.7% with stenting. 1

4. Avoid coronary stenting due to high rates of target vessel revascularization (40.1%) and inferior symptom relief compared to surgery. 1

Prognosis and Long-Term Management

• Patients with isolated myocardial bridge have excellent long-term prognosis, with major adverse cardiovascular events (death, myocardial infarction, or target vessel revascularization) occurring in only 3.4% over a median 31-month follow-up. 1

• Medical therapy alone controls symptoms in approximately 79% of patients, making invasive intervention unnecessary for the majority. 1

• Atherosclerosis develops preferentially proximal to the bridged segment due to altered shear stress, while the compressed segment itself is typically spared, so continue standard cardiovascular risk factor modification. 2